Literatur
-
1
Chiasson J L, Josse R G, Gomis R, Hanefeld M, Karasik A, Laakso M.
Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial.
Lancet.
2002;
359
2072-2077
-
2
Chiasson J L, Josse R G, Gomis R, Hanefeld M, Karasik A, Laakso M.
Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance. The STOP NIDDM trial.
JAMA.
2003;
290
486-494
-
3
Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M.
Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies.
Europ Heart J.
2004;
25: 10-16
-
5
Van de Laar F A, Lucassen P LBJ, van de Lisdonk E H, Akkermans R P, van den Hoogen H JM, Rutten G EHM, van Weel C.
How effective is acarbose in the treatment of type 2 diabetes mellitus? A Cochrane review.
Diabetes & Metabolism.
2003;
29
IDF 4S428
Prof. Dr. med. habil. H.-W. M. Breuer
Chefarzt der Abteilung für Innere Medizin, Malteser Krankenhaus St. Carolus Görlitz
Carolusstraße 212
02827 Görlitz
Phone: 03581/721002
Fax: 03581/721003
Email: breuer@carolus-goerlitz.de
